Bradley Campbell Sells 77,926 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley Campbell sold 77,926 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $10.86, for a total value of $846,276.36. Following the completion of the transaction, the chief executive officer owned 1,129,782 shares of the company’s stock, valued at $12,269,432.52. The trade was a 6.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Amicus Therapeutics Price Performance

NASDAQ:FOLD opened at $10.89 on Friday. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $11.14. The stock’s fifty day moving average is $9.36 and its two-hundred day moving average is $7.77. The company has a market capitalization of $3.36 billion, a P/E ratio of -272.18 and a beta of 0.46. The company has a quick ratio of 2.09, a current ratio of 2.99 and a debt-to-equity ratio of 1.70.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. The firm had revenue of $169.06 million during the quarter, compared to the consensus estimate of $165.24 million. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The company’s quarterly revenue was up 19.5% on a year-over-year basis. During the same period last year, the company earned $0.10 EPS. Equities analysts expect that Amicus Therapeutics, Inc. will post 0.15 EPS for the current year.

Wall Street Analysts Forecast Growth

FOLD has been the topic of a number of research analyst reports. Citigroup started coverage on shares of Amicus Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $17.00 price target on the stock. Needham & Company LLC raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Thursday, September 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Monday. JPMorgan Chase & Co. lifted their price objective on Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Finally, Zacks Research upgraded Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.29.

Hedge Funds Weigh In On Amicus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC purchased a new stake in shares of Amicus Therapeutics during the third quarter worth $43,000. Tudor Investment Corp ET AL grew its stake in Amicus Therapeutics by 5.9% during the 3rd quarter. Tudor Investment Corp ET AL now owns 168,984 shares of the biopharmaceutical company’s stock worth $1,332,000 after purchasing an additional 9,487 shares in the last quarter. Allworth Financial LP grew its stake in Amicus Therapeutics by 36.3% during the 3rd quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,246 shares in the last quarter. Swiss Life Asset Management Ltd purchased a new stake in Amicus Therapeutics during the 3rd quarter worth about $83,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in Amicus Therapeutics in the 3rd quarter valued at about $234,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.